CARsgen Therapeutics and Jaguar Gene Therapy had received incentives in 2021 to hire 200 workers each at new facilities.

Thanks to advances in imaging and diagnostic technologies, clinicians can now detect many genetic disorders in the womb, ...

Forget Vertex Pharmaceuticals -- CRISPR Therapeutics is a better buy right now.

Still, broad uptake has long been an uphill battle for the gene therapy as it competes with a variety of treatments including, Roche’s blockbuster Hemlibra, Sanofi’s newer sales driver Altuviiio and ...

RNA therapeutics target translation rather than DNA, aiming to correct shared protein production errors. By enabling cells to read through premature stop codons, engineered tRNAs could restore ...

After a rocky 2025, Sarepta Therapeutics’ executives admit they have work to do to bring patients back into the fold as sales of Duchenne muscular dystrophy gene therapy Elevidys continue to decline.

CARsgen Therapeutics and Jaguar Gene Therapy had received incentives in 2021 to hire 200 workers each at new facilities.

If you are wondering whether uniQure's current share price reflects its true worth, you are not alone. This article walks through what the numbers are really saying about the stock. The share price is ...

AMT-130 Huntington’s gene therapy data, FDA Phase III sham-trial push, cash runway, and 2026 catalysts—read now.

Will consider data that includes "the experience of individuals," FDA commissioner says ...

The first gene therapies approved to treat sickle cell disease in December 2023 are struggling on the market. But there are glimpses of forward momentum as Vertex and Genetix Bio provide updates.

Hunter Syndrome is a rare genetic condition that can cause damage to the body and the brain. It often causes children to pass away in their teens, but a UNC Health ...